ISRG Posts Earnings, Street Raises Targets as Shorts Stay Sidelined

Intuitive Surgical reported its Q3 results on October 20, and the analyst response landed within hours: a wave of target revisions that split almost evenly between upgrades and trims, all while short sellers remain a negligible presence in the stock.

The lending market tells a story of near-total indifference from bears. Short interest is 2.1% of the free float, essentially unchanged from the 2.1% flagged in the pre-earnings note four days ago, and borrow conditions are about as loose as they get. Availability runs at 7,578% of short interest, meaning shares available to lend outnumber outstanding short positions by a factor of more than 75. Borrow cost has ticked up to 0.47% from 0.27% a week ago, a 33% rise that sounds sharp but lands at a level that remains trivially cheap in absolute terms. Options positioning is equally calm. The put/call ratio is 0.80, just a fraction above its 20-day average of 0.796, and the z-score of 0.47 shows no meaningful skew in either direction. Nothing in the positioning data suggests an aggressive view on the stock from either side.

The Street's reaction to the print is where the tension sits. Most analysts kept their positive ratings intact, and several lifted targets. JP Morgan's Robbie Marcus raised to $475 from $450, maintaining Overweight. Barclays moved to $500 from $485, also Overweight. Leerink Partners went furthest, raising to $503 from $473 with an Outperform. Baird and RBC both carry $550 targets. Against that, Evercore ISI trimmed to $385 from $400 on an In-Line rating, and Mizuho cut to $400 from $415 at Neutral. The consensus mean target is $480, roughly 10% above the current price of $438, with 17 buy-equivalent ratings and no sells on the register. The analyst recommendation differential factor scores in the 98th percentile across the ORTEX universe, indicating the Street is more uniformly positive on ISRG than almost any comparable stock.

The bull case rests on the da Vinci installed-base flywheel: more than 11,000 systems placed globally, 12% installed-base growth in Q2, and a recurring revenue stream from instruments and accessories that insulates the model from single-quarter placement noise. Revenue of $2.89bn and gross margin of 70% in Q2 support that narrative. The bear case is about what the premium valuation has to absorb. The trailing P/E is near 37, price-to-book around 6.5, and EV/EBITDA at 26. Forward earnings growth expectations are moderate, the 12-month forward EPS year-on-year increase factor scores in the 38th percentile. Bears also point to US procedure volume growth slowing from 14% in Q1 to 12% in Q2, GLP-1 headwinds in bariatrics, and a projected FY27 gross headwind of $650 to $675 million. The EV/EBIT factor score of 12 reflects a valuation that leaves almost no room for operational disappointment.

Retail attention spiked sharply around the earnings date. Wikipedia views for Intuitive Surgical are running at a z-score of 2.68 against the company's own 90-day history, the highest attention reading in the dataset window. That is a measure of interest, not a revenue indicator, but it confirms the print drew broad attention beyond the institutional community. Among peers, RMD gained 4.5% on the week and SYK added 7.7%, both slightly ahead of ISRG's 3.8% move, suggesting the broader medical device sector caught a similar post-earnings tailwind rather than ISRG standing out on its own merits.

The next earnings event is not scheduled until January 19, 2027, leaving 90 days for the Street's divergence between the $385 bears and $550 bulls to play out against procedure-volume data and any update on da Vinci 5 placements.